These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16284534)

  • 1. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.
    Penzak SR; Formentini E; Alfaro RM; Long M; Natarajan V; Kovacs J
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):573-80. PubMed ID: 16284534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
    Busse KH; Formentini E; Alfaro RM; Kovacs JA; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):561-6. PubMed ID: 18645517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
    Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.
    Peytavin G; Gautran C; Otoul C; Cremieux AC; Moulaert B; Delatour F; Melac M; Strolin-Benedetti M; Farinotti R
    Eur J Clin Pharmacol; 2005 Jun; 61(4):267-73. PubMed ID: 15889300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
    Corbett AH; Patterson KB; Tien HC; Kalvass LA; Eron JJ; Ngo LT; Lim ML; Kashuba AD
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
    Ouellet D; Hsu A; Qian J; Locke CS; Eason CJ; Cavanaugh JH; Leonard JM; Granneman GR
    Br J Clin Pharmacol; 1998 Aug; 46(2):111-6. PubMed ID: 9723818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.
    Penzak SR; Hon YY; Lawhorn WD; Shirley KL; Spratlin V; Jann MW
    J Clin Psychopharmacol; 2002 Aug; 22(4):366-70. PubMed ID: 12172335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-related reduction in bupropion plasma concentrations by ritonavir.
    Park J; Vousden M; Brittain C; McConn DJ; Iavarone L; Ascher J; Sutherland SM; Muir KT
    J Clin Pharmacol; 2010 Oct; 50(10):1180-7. PubMed ID: 20484617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
    Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
    Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults.
    Rattanapunya S; Cressey TR; Rueangweerayut R; Tawon Y; Kongjam P; Na-Bangchang K
    Am J Trop Med Hyg; 2015 Dec; 93(6):1383-90. PubMed ID: 26416104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.
    Gutierrez MM; Rosenberg J; Abramowitz W
    Clin Ther; 2003 Apr; 25(4):1200-10. PubMed ID: 12809966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects.
    Schwartz JI; Mukhopadhyay S; Porras AG; Viswanathan-Aiyer KJ; Adcock S; Ebel DL; Gertz BJ
    J Clin Pharmacol; 2003 Feb; 43(2):187-92. PubMed ID: 12616672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.
    Mathias AA; West S; Hui J; Kearney BP
    Clin Pharmacol Ther; 2009 Jan; 85(1):64-70. PubMed ID: 18815591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose ritonavir moderately enhances nelfinavir exposure.
    Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
    Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.